ERCC2 and neoplasm: Genomic profiling observed potential cancer-diver gene mutations, including a somatic mutation in BRCA2 c.9097del (p.T3033Lfs*29) with a allelic frequency of 2.37%, and a germline mutation in ERCC2 c.578del (p.F193Sfs*55) with a allelic frequency of 48.3%, as well as gene amplifications of MYC (copy number: 3.27), CDK4 (copy number: 3.03) in tumor sample.